Simulations Plus (NASDAQ:SLP – Get Free Report) issued its quarterly earnings data on Wednesday. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same period in the prior year, the firm posted $0.18 EPS. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.
Simulations Plus Stock Performance
NASDAQ SLP traded down $0.94 during trading on Friday, hitting $30.02. 149,572 shares of the company’s stock traded hands, compared to its average volume of 129,462. The stock has a market capitalization of $600.70 million, a price-to-earnings ratio of 64.50 and a beta of 0.69. Simulations Plus has a 12-month low of $29.37 and a 12-month high of $51.22. The business has a 50 day moving average of $33.20 and a 200-day moving average of $40.76.
Insider Activity
In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now directly owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 60,750 shares of company stock valued at $2,145,055 over the last quarter. Company insiders own 20.90% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on Simulations Plus
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Articles
- Five stocks we like better than Simulations Plus
- What Does Downgrade Mean in Investing?
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the Nasdaq? Complete Overview with History
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a buyback in stocks? A comprehensive guide for investors
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.